{
  "KTTA": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T12:07:33Z",
      "headline": "Pasithea Therapeutics Says Safety Review Committee Recommended Phase 1 Trial Of PAS-004 Should Proceed To Cohort 5, 22mg Capsule Without Modification",
      "id": 43490691,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "KTTA"
      ],
      "updated_at": "2025-02-05T12:07:34Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43490691/pasithea-therapeutics-says-safety-review-committee-recommended-phase-1-trial-of-pas-004-should-pr",
      "added_at": "2025-02-05T12:07:38.900Z"
    }
  ],
  "EYPT": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T12:16:49Z",
      "headline": "EyePoint Pharmaceuticals Announced Six-month Results For Ongoing Phase 2 VERONA Trial Evaluating Duravyu (Vorolanib Intravitreal Insert), The Trial Met Its Primary Endpoint With Extended Time To First Supplemental Injection Compared To Aflibercept Control For Both Doses",
      "id": 43491051,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "EYPT"
      ],
      "updated_at": "2025-02-05T12:16:50Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43491051/eyepoint-pharmaceuticals-announced-six-month-results-for-ongoing-phase-2-verona-trial-evaluating-",
      "added_at": "2025-02-05T12:17:39.154Z"
    }
  ],
  "ACB": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T12:04:51Z",
      "headline": "Aurora Cannabis Q3 Global Medical Cannabis Net Revenue Up 51% YoY",
      "id": 43490554,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ACB"
      ],
      "updated_at": "2025-02-05T12:04:51Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43490554/aurora-cannabis-q3-global-medical-cannabis-net-revenue-up-51-yoy",
      "added_at": "2025-02-05T12:22:30.363Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T12:04:21Z",
      "headline": "Aurora Cannabis Q3 Total Net Revenue C$88.2M, Up 37% YoY",
      "id": 43490548,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ACB"
      ],
      "updated_at": "2025-02-05T12:04:22Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43490548/aurora-cannabis-q3-total-net-revenue-c-88-2m-up-37-yoy",
      "added_at": "2025-02-05T12:22:30.363Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T13:35:18Z",
      "headline": "Insights into Aurora Cannabis Q3 Earnings",
      "id": 43493864,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "ACB"
      ],
      "updated_at": "2025-02-05T13:35:18Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43493864/insights-into-aurora-cannabis-q3-earnings",
      "added_at": "2025-02-05T13:37:31.101Z"
    },
    {
      "author": "Vandana Singh",
      "content": "",
      "created_at": "2025-02-05T14:35:26Z",
      "headline": "Aurora Cannabis Stock Jumps On 'Record-Breaking' Q3 Earnings",
      "id": 43496003,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/05/auroracannabis.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/05/auroracannabis.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/05/auroracannabis.png"
        }
      ],
      "source": "benzinga",
      "summary": "Aurora Cannabis posted Q3 FY25 net revenue of CA$88.2 million, driven by medical cannabis and plant propagation growth, with adjusted EBITDA rising 316% to CA$23.1 million.",
      "symbols": [
        "ACB"
      ],
      "updated_at": "2025-02-05T14:35:26Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43496003/aurora-cannabis-stock-jumps-on-record-breaking-q3-earnings",
      "added_at": "2025-02-05T14:37:33.188Z"
    }
  ],
  "PRZO": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T13:01:10Z",
      "headline": "ParaZero Technologies Successfully Demonstrated Its DropAir Precision Airdrop System In Collaboration With A Leading Global Defense Company",
      "id": 43492721,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "PRZO"
      ],
      "updated_at": "2025-02-05T13:01:11Z",
      "url": "https://www.benzinga.com/news/25/02/43492721/parazero-technologies-successfully-demonstrated-its-dropair-precision-airdrop-system-in-collaboratio",
      "added_at": "2025-02-05T13:02:40.034Z"
    }
  ],
  "ACRV": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T13:01:06Z",
      "headline": "Acrivon Therapeutics Granted FDA Breakthrough Device Designation For ACR-368 OncoSignature Assay In Endometrial Cancer",
      "id": 43492712,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ACRV"
      ],
      "updated_at": "2025-02-05T13:01:07Z",
      "url": "https://www.benzinga.com/news/25/02/43492712/acrivon-therapeutics-granted-fda-breakthrough-device-designation-for-acr-368-oncosignature-assay-in",
      "added_at": "2025-02-05T13:03:26.742Z"
    }
  ],
  "CPIX": [
    {
      "author": "Vandana Singh",
      "content": "",
      "created_at": "2025-02-04T18:31:48Z",
      "headline": "Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease",
      "id": 43473776,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/04/CPIX.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/04/CPIX.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/04/CPIX.png"
        }
      ],
      "source": "benzinga",
      "summary": "Cumberland Pharmaceuticals&#39; Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.",
      "symbols": [
        "CPIX"
      ],
      "updated_at": "2025-02-04T18:31:49Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43473776/cumberland-pharmaceuticals-duchenne-candidate-shows-improved-heart-function-in-patients-with-associated-heart-disease",
      "added_at": "2025-02-05T13:15:13.529Z"
    }
  ],
  "VTGN": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T13:35:27Z",
      "headline": "Vistagen Granted US Patent For AV-101 To Treat Neuropathic Pain",
      "id": 43493874,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "VTGN"
      ],
      "updated_at": "2025-02-05T13:35:28Z",
      "url": "https://www.benzinga.com/news/25/02/43493874/vistagen-granted-us-patent-for-av-101-to-treat-neuropathic-pain",
      "added_at": "2025-02-05T13:37:40.989Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T13:35:02Z",
      "headline": "Vistagen Announces USPTO Patent Grant For AV-101 Oral Non-Opioid Neuropathic Pain Treatment, Expiring 2034",
      "id": 43493856,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "VTGN"
      ],
      "updated_at": "2025-02-05T13:35:02Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43493856/vistagen-announces-uspto-patent-grant-for-av-101-oral-non-opioid-neuropathic-pain-treatment-expir",
      "added_at": "2025-02-05T13:37:40.989Z"
    }
  ],
  "TNXP": [],
  "PCT": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T14:10:35Z",
      "headline": "PureCycle Announces $33M Financing Transaction",
      "id": 43495128,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "PCT"
      ],
      "updated_at": "2025-02-05T14:10:35Z",
      "url": "https://www.benzinga.com/news/25/02/43495128/purecycle-announces-33m-financing-transaction",
      "added_at": "2025-02-05T14:12:41.690Z"
    }
  ],
  "LEXX": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T14:17:19Z",
      "headline": "Lexaria Completes Submission To HREC For Planned Additional Of Study Arm 5 To Evaluate DehydraTECH-Tirzepatide Formulation",
      "id": 43495362,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "LEXX"
      ],
      "updated_at": "2025-02-05T14:17:20Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43495362/lexaria-completes-submission-to-hrec-for-planned-additional-of-study-arm-5-to-evaluate-dehydratec",
      "added_at": "2025-02-05T14:17:41.672Z"
    }
  ],
  "BBAI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T14:15:51Z",
      "headline": "BigBear.ai Awarded Contract By DoD's Chief Digital and Artificial Intelligence Office; Financial Terms Not Disclosed",
      "id": 43495323,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "BBAI"
      ],
      "updated_at": "2025-02-05T14:15:52Z",
      "url": "https://www.benzinga.com/news/25/02/43495323/bigbear-ai-awarded-contract-by-dods-chief-digital-and-artificial-intelligence-office-financial-terms",
      "added_at": "2025-02-05T14:18:50.550Z"
    },
    {
      "author": "Shivani Kumaresan",
      "content": "",
      "created_at": "2025-02-05T16:39:34Z",
      "headline": "BigBear.ai Pockets DoD Contract To Advance AI-Powered Threat Detection System, Stock Skyrockets",
      "id": 43501000,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/05/Other-Warnings.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/05/Other-Warnings.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/05/Other-Warnings.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": "BigBear.ai wins DoD contract to advance its VANE AI system. The contract aims to enhance the system&#39;s ability to detect trends and assess media related to potential adversaries.",
      "symbols": [
        "BBAI"
      ],
      "updated_at": "2025-02-05T16:39:35Z",
      "url": "https://www.benzinga.com/25/02/43501000/ai-based-intelligence-provider-bigbearai-partners-with-dod-to-advance-national-security",
      "added_at": "2025-02-05T16:42:37.022Z"
    }
  ],
  "SSRM": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T15:04:05Z",
      "headline": "RBC Capital Upgrades SSR Mining to Sector Perform, Raises Price Target to $8",
      "id": 43496997,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "SSRM"
      ],
      "updated_at": "2025-02-05T15:04:05Z",
      "url": "https://www.benzinga.com/news/25/02/43496997/rbc-capital-upgrades-ssr-mining-to-sector-perform-raises-price-target-to-8",
      "added_at": "2025-02-05T15:07:42.769Z"
    }
  ],
  "OSCR": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:56:34Z",
      "headline": "Oscar Health: Q4 Earnings Insights",
      "id": 43481504,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_3.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_3.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_3.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:56:34Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43481504/oscar-health-q4-earnings-insights",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:53:41Z",
      "headline": "Earnings Summary: Oscar Health Q4",
      "id": 43481293,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_1.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_1.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_1.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:53:41Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43481293/earnings-summary-oscar-health-q4",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:41:10Z",
      "headline": "Earnings Breakdown: Oscar Health Q4",
      "id": 43480379,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_1.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_1.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_1.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:41:11Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43480379/earnings-breakdown-oscar-health-q4",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:36:45Z",
      "headline": "Oscar Health Earnings Report: Q4 Overview",
      "id": 43480114,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_2.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_2.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_2.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:36:46Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43480114/oscar-health-earnings-report-q4-overview",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:32:00Z",
      "headline": "Oscar Health Q4 Earnings Assessment",
      "id": 43479837,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:32:01Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43479837/oscar-health-q4-earnings-assessment",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:27:06Z",
      "headline": "Oscar Health Earnings Review: Q4 Summary",
      "id": 43479457,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_1.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_1.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_1.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:27:07Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43479457/oscar-health-earnings-review-q4-summary",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-04T21:15:46Z",
      "headline": "Recap: Oscar Health Q4 Earnings",
      "id": 43478587,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:15:46Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43478587/recap-oscar-health-q4-earnings",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-04T21:12:00Z",
      "headline": "Oscar Health Sees FY2025 Sales $11.200B-11.300B vs $11.55B Est",
      "id": 43478421,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:12:00Z",
      "url": "https://www.benzinga.com/news/25/02/43478421/oscar-health-sees-fy2025-sales-11-200b-11-300b-vs-11-55b-est",
      "added_at": "2025-02-05T15:08:36.983Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-04T21:10:29Z",
      "headline": "Oscar Health Q4 EPS $(0.62) Misses $(0.58) Estimate, Sales $2.39B Miss $2.47B Estimate",
      "id": 43478333,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "OSCR"
      ],
      "updated_at": "2025-02-04T21:10:29Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43478333/oscar-health-q4-eps-0-62-misses-0-58-estimate-sales-2-39b-miss-2-47b-estimate",
      "added_at": "2025-02-05T15:08:36.983Z"
    }
  ],
  "RNAZ": [],
  "QNTM": [],
  "LAES": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-04T21:42:52Z",
      "headline": "SEALSQ Announces That It Has Allocated Up To $20M Of Its Available Cash To Invest In Pioneering Startups Specializing In Quantum Computing, Quantum-As-A-Service, And AI-Driven Semiconductor Technologies",
      "id": 43480542,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "LAES"
      ],
      "updated_at": "2025-02-04T21:42:53Z",
      "url": "https://www.benzinga.com/news/25/02/43480542/sealsq-announces-that-it-has-allocated-up-to-20m-of-its-available-cash-to-invest-in-pioneering-start",
      "added_at": "2025-02-05T17:07:23.037Z"
    }
  ],
  "IVVD": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T14:36:55Z",
      "headline": "Invivyd Announces A Strategic Partnership With Professional Football Coach Jim Harbaugh To Raise Awareness About the Ongoing Short And Potential Long-Term Risks Of COVID-19 To The Broad Population",
      "id": 43496055,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "IVVD"
      ],
      "updated_at": "2025-02-05T14:45:53Z",
      "url": "https://www.benzinga.com/news/25/02/43496055/invivyd-announces-a-strategic-partnership-with-professional-football-coach-jim-harbaugh-to-raise-awa",
      "added_at": "2025-02-05T18:08:30.616Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T20:45:20Z",
      "headline": "(IVVD) - Analyzing Invivyd's Short Interest",
      "id": 43508638,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/movers_image_1.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/movers_image_1.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/movers_image_1.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "IVVD"
      ],
      "updated_at": "2025-02-05T20:45:21Z",
      "url": "https://www.benzinga.com/insights/short-sellers/25/02/43508638/ivvd-analyzing-invivyds-short-interest",
      "added_at": "2025-02-05T20:47:41.840Z"
    }
  ],
  "CHGG": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T18:24:19Z",
      "headline": "Chegg Unveils AI-Powered Tools Offering Practice Questions, Custom Language Models",
      "id": 43504778,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CHGG"
      ],
      "updated_at": "2025-02-05T18:24:20Z",
      "url": "https://www.benzinga.com/news/25/02/43504778/chegg-unveils-ai-powered-tools-offering-practice-questions-custom-language-models",
      "added_at": "2025-02-05T18:27:51.252Z"
    }
  ],
  "DEI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-04T22:01:48Z",
      "headline": "Douglas Emmett Sees FY25 FFO $1.42-$1.48 Down From $1.70 YoY.",
      "id": 43481874,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "DEI"
      ],
      "updated_at": "2025-02-04T22:03:12Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43481874/douglas-emmett-sees-fy25-ffo-1-42-1-48",
      "added_at": "2025-02-05T19:24:19.812Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-04T21:59:07Z",
      "headline": "Douglas Emmett Q4 2024 FFO $0.38 Beats $0.37 Estimate, Sales $245.000 Miss $245.946M Estimate",
      "id": 43481667,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "DEI"
      ],
      "updated_at": "2025-02-04T21:59:08Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43481667/douglas-emmett-q4-2024-ffo-0-38-beats-0-37-estimate-sales-245-000-miss-245-946m-estimate",
      "added_at": "2025-02-05T19:24:19.812Z"
    }
  ],
  "APPS": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T21:06:51Z",
      "headline": "Digital Turbine Q3 Adj $0.13 Beats $(0.01) Estimate, Sales $134.64M Beat $123.68M Estimate",
      "id": 43509533,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:06:52Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43509533/digital-turbine-q3-adj-0-13-beats-0-01-estimate-sales-134-64m-beat-123-68m-estimate",
      "added_at": "2025-02-05T21:08:26.937Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T21:11:24Z",
      "headline": "Digital Turbine: Q3 Earnings Insights",
      "id": 43509705,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_4.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_4.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_4.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:11:25Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43509705/digital-turbine-q3-earnings-insights",
      "added_at": "2025-02-05T21:12:41.540Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T21:07:55Z",
      "headline": "Digital Turbine Raises FY2025 Sales Guidance from $475.00M-485.00M to $485.00M-490.00M vs $477.04M Est",
      "id": 43509586,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:07:56Z",
      "url": "https://www.benzinga.com/news/25/02/43509586/digital-turbine-raises-fy2025-sales-guidance-from-475-00m-485-00m-to-485-00m-490-00m-vs-477-04m-est",
      "added_at": "2025-02-05T21:12:53.602Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T21:16:32Z",
      "headline": "Digital Turbine Q3 Earnings Summary & Key Takeaways",
      "id": 43510056,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_1.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:16:32Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43510056/digital-turbine-q3-earnings-summary-key-takeaways",
      "added_at": "2025-02-05T21:17:42.181Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T21:21:48Z",
      "headline": "Digital Turbine Q3 Earnings Assessment",
      "id": 43510371,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_4.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_4.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_4.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:21:49Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43510371/digital-turbine-q3-earnings-assessment",
      "added_at": "2025-02-05T21:22:42.617Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T21:27:34Z",
      "headline": "Digital Turbine Q3 Earnings Report: What Investors Need to Know",
      "id": 43510952,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:27:35Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43510952/digital-turbine-q3-earnings-report-what-investors-need-to-know",
      "added_at": "2025-02-05T21:27:42.929Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T21:32:35Z",
      "headline": "Insights into Digital Turbine Q3 Earnings",
      "id": 43511340,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_3.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_3.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_3.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:32:35Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43511340/insights-into-digital-turbine-q3-earnings",
      "added_at": "2025-02-05T21:32:42.462Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-05T21:39:17Z",
      "headline": "Digital Turbine Earnings Report: Q3 Overview",
      "id": 43511771,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_3.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_3.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_3.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:39:18Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43511771/digital-turbine-earnings-report-q3-overview",
      "added_at": "2025-02-05T21:42:43.030Z"
    },
    {
      "author": "Erica Kollmann",
      "content": "",
      "created_at": "2025-02-05T21:50:01Z",
      "headline": "Digital Turbine Shares Soar After Q3 Results, Raised FY25 Revenue Outlook",
      "id": 43512566,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/05/APPS-Logo.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/05/APPS-Logo.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/05/APPS-Logo.png"
        }
      ],
      "source": "benzinga",
      "summary": "Digital Turbine announces its third-quarter financial results after Wednesday&#39;s closing bell. Here&#39;s a look at the details from the report.",
      "symbols": [
        "APPS"
      ],
      "updated_at": "2025-02-05T21:50:01Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43512566/digital-turbine-shares-soar-after-q3-results-raised-fy25-revenue-outlook",
      "added_at": "2025-02-05T21:52:43.915Z"
    }
  ],
  "RANI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-05T21:06:24Z",
      "headline": "Rani Therapeutics Announces Preclinical Data Demonstrating Oral Delivery Of Semaglutide Via RaniPill HC",
      "id": 43509511,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "RANI"
      ],
      "updated_at": "2025-02-05T21:06:24Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43509511/rani-therapeutics-announces-preclinical-data-demonstrating-oral-delivery-of-semaglutide-via-ranip",
      "added_at": "2025-02-05T21:27:02.260Z"
    }
  ]
}